Clinical Trials

Phase 2 Active not recruiting

Pancreatic Neoplasms

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

118 enrolled

Phase 1 Not yet recruiting

NSCLC

NCT07443020 2026-03-02

RIOT 4B

10 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Pleural Effusion, Malignant

NCT07431216 2026-02-24

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Phase 1/2 Not yet recruiting

68 enrolled

CNS

Glioblastoma

NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Phase 1/2 Recruiting

90 enrolled

CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT07364422 2026-01-23

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Phase 1/2 Not yet recruiting

49 enrolled

Phase NA Not yet recruiting

Stomach Neoplasms

NCT07347977 2026-01-16

LidCRM

1,400 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT07309419 2025-12-30

Cocktail-001

222 enrolled

Carcinoma, Hepatocellular

NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Phase 2 Active not recruiting

230 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Phase NA Active not recruiting

Cholangiocarcinoma

NCT01653925 2025-11-24

Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression

120 enrolled

Genitourinary

Prostatic Neoplasms

NCT03401385 2025-10-21

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Phase 1 Active not recruiting

890 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT07150247 2025-09-26

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

20 enrolled

Phase 2 Not yet recruiting

BRAF V600 Colorectal Cancer

NCT07174947 2025-09-16

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

240 enrolled

Anxiety Disorders

NCT07108959 2025-08-07

ESPB

Phase NA Not yet recruiting

40 enrolled

Breast Neoplasms

NCT06207734 2025-05-01

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

120 enrolled

Breast Neoplasms

NCT04933266 2025-04-11

Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer Surgery

Phase NA Recruiting

100 enrolled

Breast Neoplasms

NCT00302744 2025-03-13

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

12 enrolled

Anxiety Disorders, Depression, Neoplasms

NCT06813118 2025-02-06

Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case

Phase 1 Recruiting

42 enrolled

Polycystic Ovary Syndrome

NCT01973322 2025-01-09

ABSIDE

34 enrolled

Dermatologic

Melanoma

NCT04760327 2024-10-17

GynECT

Phase NA Active not recruiting

30 enrolled

Gynecological Cancers

NCT05889221 2024-09-05

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

74 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03753659 2024-07-22

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

30 enrolled

Carcinoma, Hepatocellular

NCT00596154 2024-04-01

PCNSL

33 enrolled 9 charts

Lymphoma, Non-Hodgkin

NCT05263219 2023-06-22

DEB-TACE+HAIC vs. HAIC for Large HCC

Phase 3 Unknown

230 enrolled

Carcinoma, Hepatocellular

NCT02973685 2023-06-12

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

Phase 3 Completed

315 enrolled

Carcinoma, Hepatocellular

NCT00318903 2023-05-25

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

25 enrolled

Esophageal Neoplasms

NCT03841201 2023-05-12

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT04138381 2023-03-27

SeliGIST

Phase 1/2 Unknown

30 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT03076437 2021-03-19

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

LymphoidOther hematologic neoplasm

28 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02244567 2021-02-02

U-C OC IN PCOS

Phase 1 Unknown

100 enrolled

Polycystic Ovary Syndrome

NCT01891357 2019-09-17

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Phase 2 Terminated

64 enrolled 7 charts

Carcinoma, Ductal, Breast

NCT00210353 2019-06-06

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Phase 3 Completed

454 enrolled 16 charts

Lymphoma, B-Cell, Marginal Zone

NCT03791918 2019-05-02

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

Phase 3 Withdrawn

Carcinoma, Hepatocellular

NCT00526656 2019-04-16

Sunitinib in Treating Patients With Locally Advanced Bladder Cancer

9 enrolled 5 charts

Genitourinary

Urinary Bladder Neoplasms

NCT03489616 2018-04-05

CRAGMOLC

Phase NA Unknown

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00001572 2017-07-02

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Phase 1 Completed

21 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Neoplasms, Lymphoma, B-Cell

NCT03191773 2017-06-20

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Phase 1/2 Unknown

100 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00547157 2017-03-15

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

152 enrolled 18 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

NCT00095706 2015-09-25

Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

Breast Neoplasms

NCT01544322 2015-06-18

ME-344-001

Phase 1 Completed

24 enrolled

Neoplasm Metastasis, Recurrence

NCT00210392 2015-03-30

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Phase 2 Terminated

12 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT01711398 2015-02-12

IP N02

15 enrolled

Other solid neoplasm

All Solid Tumors

NCT01558687 2014-02-04

Cilengitide Imaging Trial in Glioblastoma

Phase 1 Terminated

1 enrolled

Tumor-Agnostic

Neoplasms

NCT01027676 2013-11-14

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00203879 2013-09-05

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

19 enrolled

Dermatologic

Melanoma

NCT01401868 2013-06-24

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Phase 1 Completed

18 enrolled

Neoplasm Metastasis, Recurrence

NCT01734798 2012-11-28

Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

Phase 3 Completed

198 enrolled

Genitourinary

Locally Advanced Bladder Cancer

NCT00210327 2009-07-22

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

33 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT00167908 2009-02-04

Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer